AstraZeneca Is Not Immune to Patent Cliff
publication date: Oct 27, 2012
AstraZeneca faced revenue and earnings pressure from the loss of exclusivity of Seroquel IR. Still, the firm boasts an impressive pipeline, and management reiterated its full-year earnings guidance.
To gain access to the members only content, click here to subscribe.
You will be given immediate access to premium content on the site.